tndm-20200729
false000143813300014381332020-07-292020-07-29

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2020
 
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
 
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
11075 Roselle Street
92121
San Diego California
(Zip Code)
(Address of principal executive offices)
 Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassSymbolName of Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________



Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 29, 2020, Tandem Diabetes Care, Inc. (the "Company") announced that Peyton Howell, age 53, was elected to the Company’s Board of Directors (the “Board”) effective August 3, 2020. Ms. Howell will serve as a Class III director, with a term that expires at the Annual Meeting of Stockholders of the Company to be held in 2022 or until her earlier resignation or removal. The Board has affirmatively determined that Ms. Howell qualifies as an “independent director” under the NASDAQ Listing Rules.
 
Ms. Howell is currently the Chief Commercial and Strategy Officer at Parexel International, a leading life sciences clinical research organization. Prior to her current position, she was Executive Vice President and President of Health Systems and Specialty Care as well as Global Sourcing and Manufacturing Relations at AmerisourceBergen. Ms. Howell also served as the Director of the AmerisourceBergen Foundation during this time. Ms. Howell received a B.A. in Speech Communication from The University of Illinois at Urbana-Champaign and a Master of Health Administration from The Ohio State University.
 
We believe Ms. Howell’s experience in reimbursement and in executive management of companies in the healthcare industry, brings to our board critical skills related to scaling complex organizations and strategic planning that qualify her to serve as one of our directors.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
 
Number  Description
99.1





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:
/s/ David B. Berger
David B. Berger
Executive Vice President, Chief Legal & Compliance Officer
Date: July 30, 2020

 Document
Exhibit 99.1


Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
IR@tandemdiabetes.com


FOR IMMEDIATE RELEASE

Tandem Diabetes Care Appoints Peyton Howell to Board of Directors

San Diego, July 29, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Peyton Howell as an independent member of its board of directors effective August 3, 2020. Ms. Howell brings to the Tandem board extensive reimbursement and health insurance experience across a broad range of disease states in the in-hospital, pharmacy and home care settings.

“Peyton brings incredible value to our Board, drawing on more than 25 years of broad healthcare and leadership experience,” said John Sheridan, president and CEO, Tandem Diabetes Care. “Her appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on Tandem’s board, and we are confident she will provide valuable insight as we continue to execute our strategy to lead in insulin therapy management.”

Ms. Howell is currently the Chief Commercial and Strategy Officer at Parexel International, a leading life sciences clinical research organization. As part of her role, she leads a diabetes reimbursement consulting team that provides reimbursement support and patient assistance for a continuous glucose monitor manufacturer. Prior to her current position, she was Executive Vice President and President of Health Systems and Specialty Care as well as Global Sourcing and Manufacturing Relations at AmerisourceBergen.

Ms. Howell is a recognized national speaker on health policy and reimbursement issues. She has served as Director of the AmerisourceBergen Foundation, the National Association of Chain Drug Stores Foundation, and the Healthcare Distribution Alliance Foundation. Ms. Howell received a B.A. in Speech Communication from The University of Illinois, Champaign and a Masters of Health Administration from The Ohio State University.

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

1

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

# # #

2
v3.20.2
Cover Page Cover Page
Jul. 29, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 29, 2020
Entity Registrant Name Tandem Diabetes Care, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36189
Entity Tax Identification Number 20-4327508
Entity Address, Address Line One 11075 Roselle Street
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 366-6900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TNDM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001438133